Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases
02 avr. 2019 08h00 HE
|
Cyclerion Therapeutics, Inc.
– $175 million committed from investors in private placement offering – – Trading of CYCN begins on Nasdaq today – CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics,...